| Pioglitazone | diabetes type 2, in all type of patients | vs vildagliptin | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| all cause death, MI, stroke | no data | | cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | Heart failure | no data | | All cause death | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| Bolli, 2008 | vildagliptin (50 mg b.i.d. | pioglitazone (30 mg daily | |
| |
| Pioglitazone | | vs rosiglitazone | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| all cause death, MI, stroke | 0.40 [0.08 2.06] | p=1.00 | 0 | 735 | 1 | GLAI, | | cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | 0.50 [0.04 5.49] | p=1.00 | 0 | 735 | 1 | GLAI, | | stroke (fatal and non fatal) | 0.33 [0.01 8.14] | p=1.00 | 0 | 735 | 1 | GLAI, | | Heart failure | 0.99 [0.02 50.12] | p=1.00 | 0 | 735 | 1 | GLAI, | | All cause death | 0.50 [0.04 5.49] | p=1.00 | 0 | 735 | 1 | GLAI, |
| Trial | Studied treatment | Control | Patients |
|---|
| GLAI, | Pioglitazone | Rosiglitazone | patients with type 2 diabetes and dyslipidemia |
| |
| Pioglitazone | | vs placebo | all cause death, MI, stroke by 16% suggested Heart failure by 38% suggested | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| all cause death, MI, stroke | 0.84 [0.71 0.99] | p=0.04 | 0 | 6103 | 4 | PROactive, PNFP-026, PNFP-012, PNFP-001, | | cardiovascular events | 0.90 [0.80 1.02] | p=1.00 | 0 | 5238 | 1 | PROactive, | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | 0.79 [0.60 1.04] | p=1.00 | 0 | 6103 | 4 | PROactive, PNFP-026, PNFP-012, PNFP-001, | | stroke (fatal and non fatal) | 0.81 [0.60 1.07] | p=1.00 | 0 | 6103 | 4 | PROactive, PNFP-026, PNFP-012, PNFP-001, | | Heart failure | 1.38 [1.07 1.77] | p=0.04 | 0 | 6103 | 4 | PROactive, PNFP-026, PNFP-012, PNFP-001, | | All cause death | 0.95 [0.77 1.17] | p=1.00 | 0 | 6103 | 4 | PROactive, PNFP-026, PNFP-012, PNFP-001, |
| Trial | Studied treatment | Control | Patients |
|---|
| PROactive, 2005 | pioglitazone titrated from 15 mg to 45 mg | placebo | Inadequately controlled patients with type 2 diabetes who had evidence of macrovascular disease | | PNFP-026, | Pioglitazone | Placebo | patients with type 2 diabetes | | PNFP-012, | Pioglitazone | Placebo | patients with type 2 diabetes | | PNFP-001, | Pioglitazone | Placebo | patients with type 2 diabetes |
| |
| Pioglitazone | | vs metformin | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| all cause death, MI, stroke | no data | | cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | 0.75 [0.17 3.37] | p=1.00 | 0 | 1194 | 1 | EC404, | | stroke (fatal and non fatal) | 0.50 [0.05 5.53] | p=1.00 | 0 | 1194 | 1 | EC404, | | Heart failure | no data | | All cause death | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| EC404, | Pioglitazone | Metformin | patients with type 2 diabetes |
| |
| Pioglitazone | | vs metformin + sulfonylurea | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| all cause death, MI, stroke | no data | | cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | 0.80 [0.21 3.02] | p=1.00 | 0 | 639 | 1 | EC409, | | stroke (fatal and non fatal) | 0.14 [0.02 1.17] | p=1.00 | 0 | 639 | 1 | EC409, | | Heart failure | no data | | All cause death | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| EC409, | Pioglitazone + sulfonylurea | Metformin + sulfonylurea | patients with type 2 diabetes |
| |
| Pioglitazone | | vs placebo (add on insulin) | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| all cause death, MI, stroke | 0.71 [0.07 6.86] | p=1.00 | 0 | 788 | 2 | PNFP-014, OPI-502, | | cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | 0.71 [0.07 6.86] | p=1.00 | 0 | 788 | 2 | PNFP-014, OPI-502, | | stroke (fatal and non fatal) | 0.71 [0.04 11.38] | p=1.00 | 0 | 788 | 2 | PNFP-014, OPI-502, | | Heart failure | 2.22 [0.21 23.67] | p=1.00 | 0 | 788 | 2 | PNFP-014, OPI-502, | | All cause death | 0.71 [0.04 11.38] | p=1.00 | 0 | 788 | 2 | PNFP-014, OPI-502, |
| Trial | Studied treatment | Control | Patients |
|---|
| PNFP-014, | Pioglitazone insulin | Placebo + insulin | patients with type 2 diabetes | | OPI-502, | Pioglitazone + insulin | Placebo + insulin | Insulin-dependent DM-2 |
| |
| Pioglitazone | | vs placebo (add on MET) | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| all cause death, MI, stroke | 0.95 [0.02 48.29] | p=1.00 | 0 | 328 | 1 | PNFP-027, | | cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | 0.95 [0.02 48.29] | p=1.00 | 0 | 328 | 1 | PNFP-027, | | stroke (fatal and non fatal) | 0.95 [0.02 48.29] | p=1.00 | 0 | 328 | 1 | PNFP-027, | | Heart failure | 2.86 [0.12 70.66] | p=1.00 | 0 | 328 | 1 | PNFP-027, | | All cause death | 0.95 [0.02 48.29] | p=1.00 | 0 | 328 | 1 | PNFP-027, |
| Trial | Studied treatment | Control | Patients |
|---|
| PNFP-027, | Pioglitazone + metforminrea | Placebo +metformin | patients with type 2 diabetes |
| |
| Pioglitazone | | vs sulfonylurea | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| all cause death, MI, stroke | 0.88 [0.54 1.44] | p=1.00 | 0 | 3175 | 3 | PNFP-010, OPI-504, OPI-506, | | cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | 0.83 [0.44 1.55] | p=1.00 | 0 | 5227 | 6 | PNFP-010, OPI-504, EC405, OPI-501, OPI-520, OPI-506, | | stroke (fatal and non fatal) | 1.26 [0.59 2.71] | p=1.00 | 0 | 5227 | 6 | PNFP-010, OPI-504, EC405, OPI-501, OPI-520, OPI-506, | | Heart failure | 1.56 [0.89 2.73] | p=1.00 | 0 | 3175 | 3 | PNFP-010, OPI-504, OPI-506, | | All cause death | 0.96 [0.44 2.10] | p=1.00 | 0 | 3175 | 3 | PNFP-010, OPI-504, OPI-506, |
| Trial | Studied treatment | Control | Patients |
|---|
| PNFP-010, | Pioglitazone + sulfonylurea | Sulfonylurea | patients with type 2 diabetes | | OPI-504, | Pioglitazone | Sulfonylurea | patients with type 2 diabetes andmild to moderate congestive heart failure | | EC405, | Pioglitazone | Sulfonylurea | patients with type 2 diabetes | | OPI-501, | Pioglitazone | Sulfonylurea | Recently diagnosed DM-2 | | OPI-520, | Pioglitazone | Sulfonylurea | Inadequately controlled DM-2 with mild cardiac disease(New York HeartAssociation Class I) | | OPI-506, 0 | Pioglitazone | Sulfonylurea | Inadequately controlled DM-2 |
| |
| Pioglitazone | | vs sulfonylurea + metformin | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| all cause death, MI, stroke | no data | | cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | 4.94 [0.57 42.50] | p=1.00 | 0 | 630 | 1 | EC410, | | stroke (fatal and non fatal) | 0.66 [0.11 3.97] | p=1.00 | 0 | 630 | 1 | EC410, | | Heart failure | no data | | All cause death | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| EC410, | Pioglitazone + metformin | Sulfonylurea + metformin | patients with type 2 diabetes |
| |
| Pioglitazone | | vs glimepiride | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| all cause death, MI, stroke | 0.83 [0.25 2.75] | p=1.00 | 0 | 547 | 1 | PERISCOPE, | | cardiovascular events | 0.84 [0.37 1.92] | p=1.00 | 0 | 547 | 1 | PERISCOPE, | | Cardiovascular death | 2.99 [0.31 28.92] | p=1.00 | 0 | 547 | 1 | PERISCOPE, | | myocardial infarction (fatal and non fatal) | 0.50 [0.09 2.74] | p=1.00 | 0 | 547 | 1 | PERISCOPE, | | stroke (fatal and non fatal) | 0.33 [0.01 8.19] | p=1.00 | 0 | 547 | 1 | PERISCOPE, | | Heart failure | 0.80 [0.21 3.00] | p=1.00 | 0 | 547 | 1 | PERISCOPE, | | All cause death | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| PERISCOPE, 2008 | pioglitazone 15 to 45 mg | glimepiride, 1 to 4 mg | patients with coronary disease and type 2 diabetes |
| |
| Pioglitazone | diabetes type 2, in patients with cardiovascular disease | vs placebo | Heart failure by 39% suggested | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| all cause death, MI, stroke | 0.85 [0.72 1.00] | p=1.00 | 0 | 5238 | 1 | PROactive, | | cardiovascular events | 0.90 [0.80 1.02] | p=1.00 | 0 | 5238 | 1 | PROactive, | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | 0.82 [0.62 1.07] | p=1.00 | 0 | 5238 | 1 | PROactive, | | stroke (fatal and non fatal) | 0.81 [0.61 1.08] | p=1.00 | 0 | 5238 | 1 | PROactive, | | Heart failure | 1.39 [1.08 1.80] | p=0.04 | 0 | 5238 | 1 | PROactive, | | All cause death | 0.96 [0.78 1.19] | p=1.00 | 0 | 5238 | 1 | PROactive, |
| Trial | Studied treatment | Control | Patients |
|---|
| PROactive, 2005 | pioglitazone titrated from 15 mg to 45 mg | placebo | Inadequately controlled patients with type 2 diabetes who had evidence of macrovascular disease |
| |
| Pioglitazone | | vs sulfonylurea | Heart failure by 161% suggested | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| all cause death, MI, stroke | 1.47 [0.65 3.33] | p=1.00 | 0 | 518 | 1 | OPI-504, | | cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | 1.68 [0.47 5.96] | p=1.00 | 0 | 818 | 2 | OPI-504, OPI-520, | | stroke (fatal and non fatal) | 1.90 [0.16 22.72] | p=1.00 | 0 | 818 | 2 | OPI-504, OPI-520, | | Heart failure | 2.61 [1.19 5.72] | p=0.04 | 0 | 518 | 1 | OPI-504, | | All cause death | 1.59 [0.65 3.90] | p=1.00 | 0 | 518 | 1 | OPI-504, |
| Trial | Studied treatment | Control | Patients |
|---|
| OPI-504, | Pioglitazone | Sulfonylurea | patients with type 2 diabetes andmild to moderate congestive heart failure | | OPI-520, | Pioglitazone | Sulfonylurea | Inadequately controlled DM-2 with mild cardiac disease(New York HeartAssociation Class I) |
| |
| Pioglitazone | | vs glimepiride | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| all cause death, MI, stroke | 0.83 [0.25 2.75] | p=1.00 | 0 | 547 | 1 | PERISCOPE, | | cardiovascular events | 0.84 [0.37 1.92] | p=1.00 | 0 | 547 | 1 | PERISCOPE, | | Cardiovascular death | 2.99 [0.31 28.92] | p=1.00 | 0 | 547 | 1 | PERISCOPE, | | myocardial infarction (fatal and non fatal) | 0.50 [0.09 2.74] | p=1.00 | 0 | 547 | 1 | PERISCOPE, | | stroke (fatal and non fatal) | 0.33 [0.01 8.19] | p=1.00 | 0 | 547 | 1 | PERISCOPE, | | Heart failure | 0.80 [0.21 3.00] | p=1.00 | 0 | 547 | 1 | PERISCOPE, | | All cause death | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| PERISCOPE, 2008 | pioglitazone 15 to 45 mg | glimepiride, 1 to 4 mg | patients with coronary disease and type 2 diabetes |
| |
| Rosiglitazone | diabetes type 2, in all type of patients | vs control | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| all cause death, MI, stroke | no data | | cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | Heart failure | no data | | All cause death | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| Wang, 2005 | rosiglitazone 4 mg/d | control | patients with diabetes and CAD who had undergone percutaneous coronary intervention |
| |
| Rosiglitazone | | vs | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| all cause death, MI, stroke | no data | | cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | Heart failure | no data | | All cause death | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| AVM100264 , | Rosiglitazone and metformin | Metformin and sulfonylurea | Overweight patients with type 2 DM poorly controlled on Met | | BRL 49653C/185 , | Rosiglitazone with or without metformin | Usual care with or without metformin | patients with type 2 diabetes | | SB-712753/007 , | Rosiglitazone with or without metformin | Metformin | patients with type 2 diabetes without previous drug therapy | | SB-712753/009 , | Rosiglitazone, metformin, and insulin | Insulin | patients with type 2 diabetes with insulin |
| |
| Rosiglitazone | | vs glyburide | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| all cause death, MI, stroke | no data | | cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | Heart failure | no data | | All cause death | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| 49653/020 , | Rosiglitazone | Glyburide | patients with type 2 diabetes | | 49653/143 , | Rosiglitazone and glyburide | Glyburide | Type 2 DM poorly controlled on glyburide | | 49653/079 , | Rosiglitazone with or without glyburide | Glyburide | patients with type 2 diabetes poorly controlled on maximum dose of Gly | | 49653/080 , | Rosiglitazone | Glyburide | patients with type 2 diabetes | | 49653/097 , | Rosiglitazone | Glyburide | patients with type 2 diabetesDM |
| |
| Rosiglitazone | | vs glyburide (add on MET) | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| all cause death, MI, stroke | no data | | cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | Heart failure | no data | | All cause death | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| 49653/137 , | Rosiglitazone and metformin | Glyburide and metformin | patients with type 2 diabetes |
| |
| Rosiglitazone | | vs metformin | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| all cause death, MI, stroke | no data | | cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | Heart failure | no data | | All cause death | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| 49653/093 , | Rosiglitazone with or without metformin | Metformin | patients with type 2 diabetes poorly controlled on Met | | 49653/094 , | Rosiglitazone and metformin | Metformin | Type 2 DM poorly controlled on Met |
| |
| Rosiglitazone | | vs placebo | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| all cause death, MI, stroke | no data | | cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | Heart failure | no data | | All cause death | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| 49653/011 , | Rosiglitazone | Placebo | patients with type 2 diabetes | | BRL 49653/334 , | Rosiglitazone | Placebo | patients with type 2 diabetes or insulin resistance syndrome | | 49653/128 , | Rosiglitazone | Placebo | patients with type 2 diabetes on concurrent Su | | 49653/134 , | Rosiglitazone | Placebo | patients with type 2 diabetes on Gly and Met | | 49653/136 , | Rosiglitazone | Placebo | patients with type 2 diabetes and chronic renal failure on Su, insulin, or both | | 49653/330 , | Rosiglitazone | Placebo | Chronic psoriasis | | 49653/331 , | Rosiglitazone | Placebo | Chronic psoriasis | | AVA100193 , | Rosiglitazone | Placebo | Mild-to-moderate Alzheimer’s disease |
| |
| Rosiglitazone | | vs placebo (add on glicazide) | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| all cause death, MI, stroke | no data | | cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | Heart failure | no data | | All cause death | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| 49653/145 , | Rosiglitazone and gliclazide | Gliclazide | patients with type 2 diabetes |
| |
| Rosiglitazone | | vs placebo (add on glimepiride) | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| all cause death, MI, stroke | no data | | cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | Heart failure | no data | | All cause death | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| 49653/234 , | Rosiglitazone and glimepiride | Glimepiride | patients with type 2 diabetes |
| |
| Rosiglitazone | | vs placebo (add on glipizide) | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| all cause death, MI, stroke | no data | | cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | Heart failure | no data | | All cause death | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| 49653/135 , | Rosiglitazone and glipizide | Glipizide | Elderly patients with type 2 DM |
| |
| Rosiglitazone | | vs placebo (add on glyburide) | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| all cause death, MI, stroke | no data | | cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | Heart failure | no data | | All cause death | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| 100684 , | Rosiglitazone and glyburide | Glyburide | Korean patients with type 2 DM | | 49653/127 , | Rosiglitazone and glyburide | Glyburide | patients with type 2 diabetespoorly controlled on Gly | | 49653/162 , | Rosiglitazone and glyburide | Glyburide | patients with type 2 diabetes |
| |
| Rosiglitazone | | vs placebo (add on insulin) | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| all cause death, MI, stroke | no data | | cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | Heart failure | no data | | All cause death | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| BRL 49653/347 , | Rosiglitazone and insulin | Insulin | patients with type 2 diabetes poorly controlled on insulin | | 49653/085 , | Rosiglitazone and insulin | Insulin | patients with type 2 diabetes | | 49653/095 , | Rosiglitazone and insulin | Insulin | patients with type 2 diabetes poorly controlled on insulin |
| |
| Rosiglitazone | | vs placebo (add on MET) | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| all cause death, MI, stroke | no data | | cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | Heart failure | no data | | All cause death | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| 49653/284 , | Rosiglitazone and metformin | Metformin | patients with type 2 diabetes | | 712753/008 , | Rosiglitazone and metformin | Metformin | Type 2 DM poorly controlled on Met | | SB-712753/002 , | Rosiglitazone and metformin | Metformin | patients with type 2 diabetes poorly controlled | | SB-712753/003 , | Rosiglitazone and metformin | Metformin | Mild type 2 DM |
| |
| Rosiglitazone | | vs placebo (add on SU) | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| all cause death, MI, stroke | no data | | cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | Heart failure | no data | | All cause death | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| 49653/015 , | Rosiglitazone and sulfonylurea | Sulfonylurea | patients with type 2 diabetes | | 49653/125 , | Rosiglitazone and sulfonylurea | Sulfonylurea | patients with type 2 diabetes | | 49653/147 , | Rosiglitazone and sufonylurea | Sulfonylurea | Indo-Asian patients with type 2 diabetes | | 49653/132 , | Rosiglitazone and sulfonylurea | Sulfonylurea | Patients in China with type 2 DM |
| |
| Rosiglitazone | | vs usual care | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| all cause death, MI, stroke | no data | | cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | Heart failure | no data | | All cause death | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| 49653/211 , | Rosiglitazone and usual care | Usual care | Type 2 DM with CHF |
| |
| Rosiglitazone | | vs glipizide | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| all cause death, MI, stroke | no data | | cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | Heart failure | no data | | All cause death | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| APPROACH, 2008 | rosiglitazone at up to 8 mg/day | glipizide at 15 mg/day | patients with type 2 diabetes and coronary artery disease |
| |
| Rosiglitazone | | vs standard glucose-lowering drugs | Heart failure by 49% suggested | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| all cause death, MI, stroke | no data | | cardiovascular events | 1.05 [0.90 1.22] | p=1.00 | 0 | 8798 | 2 | ADOPT, RECORD, | | Cardiovascular death | 0.85 [0.60 1.20] | p=1.00 | 0 | 4447 | 1 | RECORD, | | myocardial infarction (fatal and non fatal) | 1.22 [0.91 1.65] | p=1.00 | 0 | 8798 | 2 | ADOPT, RECORD, | | stroke (fatal and non fatal) | 0.77 [0.55 1.07] | p=1.00 | 0 | 8798 | 2 | ADOPT, RECORD, | | Heart failure | 1.49 [1.15 1.94] | p=0.04 | 0 | 8798 | 2 | ADOPT, RECORD, | | All cause death | 0.87 [0.69 1.10] | p=1.00 | 0 | 4447 | 1 | RECORD, |
| Trial | Studied treatment | Control | Patients |
|---|
| ADOPT, 2006 | Rosiglitazone 4mg twice daily | Metformin 1000mg twice daily or glyburide 7.5mg twice daily | Recently diagnosed type type 2 diabetes | | RECORD, 2009 | addition of rosiglitazone (4-8 mg daily titrated) to metformin or sulfonylurea, target HbA1c<=7·0% | combination of metformin and sulfonylurea, target HbA1c<=7·0% | patients with type 2 diabetes onmonotherapy with either metformin or sulfonylurea andin less than optimal blood glucose control (HbA1c >7·0–9·0%) |
| |
| Rosiglitazone | diabetes type 2, in patients with cardiovascular disease | vs control | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| all cause death, MI, stroke | no data | | cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | Heart failure | no data | | All cause death | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| Wang, 2005 | rosiglitazone 4 mg/d | control | patients with diabetes and CAD who had undergone percutaneous coronary intervention |
| |
| Rosiglitazone | | vs glipizide | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| all cause death, MI, stroke | no data | | cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | Heart failure | no data | | All cause death | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| APPROACH, 2008 | rosiglitazone at up to 8 mg/day | glipizide at 15 mg/day | patients with type 2 diabetes and coronary artery disease |
| |
